Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00168064
Other study ID # 2005NMMF-201-US
Secondary ID
Status Completed
Phase Phase 2
First received September 7, 2005
Last updated October 2, 2012
Start date May 2006
Est. completion date August 2011

Study information

Verified date October 2012
Source Yaupon Therapeutics
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This study will evaluate the efficacy, tolerability and safety of the topical application of mechlorethamine (MCH) formulations in patients with stage I or IIA mycosis fungoides (MF).


Description:

The successful use of mechlorethamine (MCH) as a topical agent in the treatment of mycosis fungoides, a form of cutaneous T-cell lymphoma, was first reported in the late 1950s, and provided a rationale for skin-directed chemotherapy that minimized systemic toxicity. Since then, multiple investigators have demonstrated the safety and efficacy of topically applied MCH in the treatment of mycosis fungoides. This study will evaluate the efficacy (non-inferiority), tolerability and safety of topical application of MCH proprietary gel versus a compounded ointment formulation in Aquaphor in patients with stage I or IIA MF.


Recruitment information / eligibility

Status Completed
Enrollment 260
Est. completion date August 2011
Est. primary completion date August 2010
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients with mycosis fungoides confirmed by a skin biopsy

- Stage I or IIA patients must have been treated previously with prior topical therapies including PUVA, UVB, topical steroids, but not NM within the past 2 years, or topical carmustine (BCNU)

- Patients must be otherwise healthy with acceptable organ function.

- Prior to initiating study therapy, patients must not have had topical therapy within four weeks

- Lab values within normal range

- Willing/able to give consent

- Must use effective means of contraception if of childbearing potential

Exclusion Criteria:

- Newly diagnosed mycosis fungoides with no prior therapy

- A prior history of treatment with topical NM within the past 2 years or topical carmustine (BCNU)

- Use of topical or systemic therapies for MF within four (4) weeks of entry in the study

- Patients with a diagnosis of stage IIB-IV MF

- Serious known concurrent medical illness or infection, which could potentially present a safety risk and/or prevent compliance with the requirements of the treatment program

- Pregnant or nursing females, or males and females of childbearing potential, not using an effective means of contraception

- Patients who have had radiation therapy within one year of study start

- Patients who have a history of a higher T score than T2 or a higher N score than N1

- Patients who do not agree to do all labs at one site

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
mechlorethamine-MCH (nitrogen mustard)
All affected areas (lesions) are to be treated once daily for twelve months with mechlorethamine-MCH (nitrogen mustard) 0.02% PG or NM 0.02% AP ointment

Locations

Country Name City State
United States Northwestern University - Dept. of Dermatology Chicago Illinois
United States University of Texas, Southwestern Medical Center Dallas Texas
United States Duke University Medical Center Durham North Carolina
United States The University of Texas, M.D. Anderson Cancer Center Houston Texas
United States University of Wisconsin Madison Wisconsin
United States Columbia University, Dept. of Dermatology New York New York
United States NYU Medical Center Dept. of Dermatology New York New York
United States Fox Chase Cancer Center Philadelphia Pennsylvania
United States University of Pennsylvania Philadelphia Pennsylvania
United States Utah Clinical Trials, LLC Salt Lake City Utah
United States Stanford University Medical Center Stanford California
United States Oklahoma University Tulsa Oklahoma

Sponsors (1)

Lead Sponsor Collaborator
Yaupon Therapeutics

Country where clinical trial is conducted

United States, 

References & Publications (3)

Kim YH, Jensen RA, Watanabe GL, Varghese A, Hoppe RT. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol. 1996 Nov;132(11):1309-13. — View Citation

Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003 Feb;139(2):165-73. — View Citation

Kim YH. Management with topical nitrogen mustard in mycosis fungoides. Dermatol Ther. 2003;16(4):288-98. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Ratio of Response Rates Based on CAILS The ratio of the response rate of the patients treated with the PG formulation to the response rate of the patients treated with the AP formulation. Skin response determined by at least a 50% reduction from baseline in the Composite Assessment of Index Lesion Severity (CAILS) following up to 12 months of treatment Assessment made at Day 1 and every subsequent visit during treatment No
Secondary Severity-weighted Assessment Tool (SWAT) Within up to 12 Months by 2 or More Consecutive Observations Over at Least 4 Weeks Assessment made at Day 1 and every subsequent visit during treatment Yes
Secondary Percent of Participants Achieving at Least 50% Improvement of Severity Weighted Assessment Tool (SWAT) Assessment of lesion distribution and severity. A responder analysis was performed on whether subject achieved at least 50% improvement on scale. This had to be confirmed on at least one visit at least 4 weeks apart. Baseline to end of therapy No
See also
  Status Clinical Trial Phase
Terminated NCT02890368 - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Phase 1
Not yet recruiting NCT02881749 - Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides Phase 2
Completed NCT00051012 - Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients Phase 4
Terminated NCT03789864 - Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides N/A
Completed NCT01590732 - Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma Phase 1
Recruiting NCT02848274 - ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Recruiting NCT00177268 - Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Recruiting NCT05357794 - Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides Phase 2
Completed NCT04955340 - A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat Phase 1
Recruiting NCT04960618 - Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome Phase 2
Completed NCT02883517 - Cell-free Circulating DNA in Primary Cutaneous Lymphomas
Active, not recruiting NCT02953301 - Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) Phase 2
Completed NCT00254332 - Effect of Denileukin Diftitox on Immune System in CTCL Patients N/A
Completed NCT02296164 - Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma
Recruiting NCT05680558 - Photopheresis in Early-stage Mycosis Fungoides Phase 2
Completed NCT00038376 - Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies Phase 2
Recruiting NCT05879458 - Ritlecitinib in CTCL Phase 2
Recruiting NCT05904522 - Histopathological Changes in Mycosis Fungoides N/A
Recruiting NCT05414500 - Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides Phase 1
Recruiting NCT04256018 - Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome Phase 2